Tower Research Capital LLC TRC lowered its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 40.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,805 shares of the biopharmaceutical company’s stock after selling 4,581 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Celldex Therapeutics were worth $192,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in Celldex Therapeutics by 109.0% in the third quarter. Nisa Investment Advisors LLC now owns 1,024 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 534 shares during the last quarter. Point72 Hong Kong Ltd raised its position in Celldex Therapeutics by 57.9% in the first quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 511 shares during the period. Great West Life Assurance Co. Can purchased a new position in Celldex Therapeutics in the third quarter valued at about $58,000. Atlas Capital Advisors LLC purchased a new position in Celldex Therapeutics in the third quarter valued at about $76,000. Finally, Virtus ETF Advisers LLC raised its position in Celldex Therapeutics by 16.6% in the second quarter. Virtus ETF Advisers LLC now owns 4,816 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 685 shares during the period.
Wall Street Analysts Forecast Growth
CLDX has been the topic of several research reports. Guggenheim cut their price objective on Celldex Therapeutics from $68.00 to $63.00 and set a “buy” rating on the stock in a research report on Friday, November 11th. StockNews.com raised Celldex Therapeutics to a “sell” rating in a research report on Tuesday, December 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $73.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, March 1st.
Celldex Therapeutics Stock Down 3.8 %
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
- Get a free copy of the StockNews.com research report on Celldex Therapeutics (CLDX)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.